Aarti Pharmalabs Ltd (AARTIPHARM) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported a 9% YoY revenue growth in Q4 FY26, driven by the highest-ever quarterly performance in the Xanthine Derivatives and CDMO/CMO segments.
- Profitability was impacted during the quarter, with a decline in both EBITDA and Profit After Tax, primarily due to rising raw material costs, logistics hurdles from geopolitical tensions, and costs associated with the ramp-up of new facilities.
- The CDMO/CMO segment demonstrated strong momentum, achieving its highest-ever quarterly revenue and showing a robust 32% YoY growth for the full financial year, underscoring its role as a key growth driver.
- Significant capital expenditure of approximately INR 400 crores was incurred in FY26 for major expansion projects, including the Xanthine capacity enhancement and the new Atali facility, which are expected to drive future growth.
- The company has provided a long-term growth guidance of 15-18% for both revenue and EBITDA over the next 3-4 years, with the CDMO/CMO business projected to lead this growth with a 40-50% increase in FY27.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.